Iron chelation therapy
European Journal of Haematology · 2023
DOI: 10.1111/ejh.13935 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Antonella Bruzzese und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-hematology, A.O. of Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: Chelation Therapy, Iron Overload. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 71 Literaturangaben.
Abstract (Originalsprache)
Iron overload is a pathological condition resulting from a congenital impairment of its regulation, increased intestinal iron absorption secondary to bone marrow erythroid hyperplasia, or a chronic transfusional regimen. In normal conditions, intracellular and systemic mechanisms contribute to maintaining iron balance. When this complex homeostatic mechanism fails, an iron overload could be present. Detecting an iron overload is not easy. The gold standard remains the liver biopsy, even if it is invasive and dangerous. Identifying iron using noninvasive techniques allowed a better understanding of the rate of iron overload in different organs, with a low risk for the patient. Estimating serum ferritin (mg/L) is the easiest and, consequently, the most employed diagnostic tool for assessing body iron stores, even if it could be a not specific method. The most common hematological causes of iron overload are myelodysplastic syndromes, sickle cell disease, and thalassemia. In all of these conditions, three drugs have been approved for the treatment of iron overload: deferiprone, deferoxamine, and deferasirox. These chelators have been demonstrated to help lower tissue iron levels and prevent iron overload complications, improving event‐free survival (EFS). Nowadays, the decision to start chelation and which chelator to choose remains the joint decision of the clinician and patient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Department of Onco-hematology, A.O. of Cosenza, Cosenza, Italy.
- Internal Medicine Department, AO of Cosenza, Cosenza, Italy.
- General Hospital Management, AO of Cosenza, Cosenza, Italy.
- SOC Ematologia Azienda USL-IRCSS di Reggio Emilia, Reggio Emilia, Emilia Romagna, Italy.
- Scientific Direction Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Emilia Romagna, Italy.
- Biotechnology Research Unit, Aprigliano, A.O./ASP of Cosenza, Cosenza, Italy.
ORCID-Profile: Antonella Bruzzese, Isabella Capodanno, Fortunato Morabito
Zitieren
APA
Bruzzese, A., Martino, E. A., Mendicino, F., Lucia, E., Olivito, V., Bova, C., Filippelli, G., Capodanno, I., Neri, A., Morabito, F., Gentile, M., & Vigna, E. (2023). Iron chelation therapy. European Journal of Haematology. https://doi.org/10.1111/ejh.13935
Vancouver
Bruzzese A, Martino EA, Mendicino F, Lucia E, Olivito V, Bova C, et al. Iron chelation therapy. European Journal of Haematology. 2023. doi:10.1111/ejh.13935
BibTeX
@article{Bruzzese2023,
author = {Bruzzese, Antonella and Martino, Enrica Antonia and Mendicino, Francesco and Lucia, Eugenio and Olivito, Virginia and Bova, Carlo and Filippelli, Gianfranco and Capodanno, Isabella and Neri, Antonino and Morabito, Fortunato and Gentile, Massimo and Vigna, Ernesto},
title = {Iron chelation therapy},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.13935}
}
EUVIMED